Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Enlivex Therapeutics Ltd ENLV

Healthcare Biotechnology
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages... see more

Recent & Breaking News (NDAQ:ENLV)

Enlivex Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece

GlobeNewswire December 7, 2021

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Treatment of Sepsis Patients with Allocetra

GlobeNewswire December 6, 2021

Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update

GlobeNewswire November 22, 2021

Spanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain

GlobeNewswire November 10, 2021

Spanish Regulator Grants Enlivex Authorization To Expand Its Sepsis Phase II into Spain

GlobeNewswire November 4, 2021

Enlivex CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer-BioNTech COVID-19 Vaccine in The New England Journal of Medicine

GlobeNewswire October 12, 2021

Enlivex Receives Notice of Allowance for Israeli Patent Application Covering Allocetra Derived from Pooled Donor Cells

GlobeNewswire October 5, 2021

Enlivex Announces the Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data from Phase Ib Trial Evaluating Allocetra in Patients with Sepsis

GlobeNewswire October 4, 2021

Enlivex to Present at Reuters Events' Cell & Gene Therapy USA 2021

GlobeNewswire September 29, 2021

Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS

GlobeNewswire September 22, 2021

Enlivex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 9, 2021

Enlivex: After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of a Multi-Center, Randomized Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients

GlobeNewswire August 15, 2021

Enlivex Announces Second Quarter 2021 Financial Results and Provides a Business Update

GlobeNewswire August 9, 2021

Enlivex Hires Biotech Industry Veteran Tzvi Palash to Lead the Design and Construction of its New cGMP Allocetra Manufacturing Plant

GlobeNewswire August 2, 2021

Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021

GlobeNewswire July 21, 2021

Enlivex to Present at the ARDS Drug Development Summit 2021

GlobeNewswire July 14, 2021

Enlivex Initiates Design and Construction Process for a New cGMP Allocetra Manufacturing Plant

GlobeNewswire July 12, 2021

Enlivex Annouces Participation in A.G.P.'s Upcoming 2021 Virtual Summer Healthcare Symposium

GlobeNewswire June 16, 2021

Enlivex Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Cancer

GlobeNewswire June 15, 2021

Enlivex to Present at the Jefferies 2021 Virtual Healthcare Conference

GlobeNewswire June 3, 2021